Lorundrostat at cost-effectiveness threshold prices
Baxdrostat at cost-effectiveness threshold prices
“At the $50,000 per evLY threshold price when compared to spironolactone ($1,000), eplerenone ($1,200), and amiloride ($1,200), approximately 55%, 45%, and 45% of eligible patients could be treated respectively. At the $200,000 per evLY threshold price when compared to spironolactone ($3,000), eplerenone ($1,900), and amiloride ($3,100), approximately 9%, 17%, and 8% of eligible patients could be treated respectively.” (opens the source at this quote in a new tab)